[go: up one dir, main page]

MX2018016183A - Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. - Google Patents

Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.

Info

Publication number
MX2018016183A
MX2018016183A MX2018016183A MX2018016183A MX2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A MX 2018016183 A MX2018016183 A MX 2018016183A
Authority
MX
Mexico
Prior art keywords
methods
antibodies
same
fragments
specific antibodies
Prior art date
Application number
MX2018016183A
Other languages
English (en)
Inventor
Belk Jonathan
J Sharkey Nathan
Gorelik Leonid
Original Assignee
Checkpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkpoint Therapeutics Inc filed Critical Checkpoint Therapeutics Inc
Publication of MX2018016183A publication Critical patent/MX2018016183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripcion se refiere generalmente a anticuerpos y fragmentos de union funcionales de los mismos que se unen al ligando 1 de muerte programada (PD-L1); en particular, los anticuerpos y fragmentos descritos se unen al PD-L1 de humano, y comprenden regiones determinantes de complementariedad (CDRs) novedosas; finalmente, la presente descripcion se refiere a administrar los anticuerpos y fragmentos descritos a sujetos con cancer, de esta manera tratando o retardando la progresion o proliferacion del cancer.
MX2018016183A 2016-06-29 2017-06-28 Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. MX2018016183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356105P 2016-06-29 2016-06-29
PCT/US2017/039810 WO2018005682A2 (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
MX2018016183A true MX2018016183A (es) 2019-06-10

Family

ID=60785529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016183A MX2018016183A (es) 2016-06-29 2017-06-28 Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.

Country Status (13)

Country Link
US (3) US10590199B2 (es)
EP (1) EP3478723B1 (es)
JP (2) JP7148414B2 (es)
KR (2) KR102422411B1 (es)
CN (1) CN109641960A (es)
AU (2) AU2017290709B2 (es)
BR (1) BR112018076684A2 (es)
CA (1) CA3027204A1 (es)
IL (3) IL276515B2 (es)
MX (1) MX2018016183A (es)
RU (1) RU2749109C2 (es)
SG (2) SG11201810927QA (es)
WO (1) WO2018005682A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
IL276515B2 (en) * 2016-06-29 2025-11-01 Checkpoint Therapeutics Inc Pd-l1-specific antibodies and methods of using the same
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
KR20240162586A (ko) * 2018-10-31 2024-11-15 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
WO2020102387A1 (en) * 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
KR102207478B1 (ko) * 2019-03-13 2021-01-26 한국도로공사 시간 정보를 활용한 톨링 시스템 및 그의 구동 방법
BR112021005365A2 (pt) 2019-04-26 2021-11-16 I Mab Biopharma Us Ltd Anticorpo ou fragmento de ligação ao antígeno do mesmo, anticorpo biespecífico, composição, um ou mais polinucleotídeos, célula isolada, método para tratar câncer ou infecção, e, uso do anticorpo ou fragmento do mesmo ou da composição
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
CN113121686B (zh) * 2019-12-31 2025-12-02 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
CA3187850A1 (en) * 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
KR20250140097A (ko) 2023-01-30 2025-09-24 키맵 리미티드 항체
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN103145842A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
HRP20151102T1 (xx) * 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
CA2627890A1 (en) 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
HRP20171653T1 (hr) * 2009-11-24 2017-12-15 Medimmune Limited Vezna sredstva koja služe ciljano protiv b7-h1
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
BR112014029883B1 (pt) * 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
MX2017011644A (es) * 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
CA3009661A1 (en) * 2016-01-11 2017-07-20 Inhibrx, Inc. Multivalent and multispecific 41bb-binding fusion proteins
MX2018015592A (es) * 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
IL276515B2 (en) * 2016-06-29 2025-11-01 Checkpoint Therapeutics Inc Pd-l1-specific antibodies and methods of using the same
JP2019526595A (ja) * 2016-09-09 2019-09-19 ティージー セラピューティクス，インコーポレイテッド 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ

Also Published As

Publication number Publication date
KR20190028716A (ko) 2019-03-19
SG10202100100UA (en) 2021-02-25
IL276515A (en) 2020-09-30
RU2019102009A3 (es) 2020-12-14
IL276515B2 (en) 2025-11-01
US10590199B2 (en) 2020-03-17
EP3478723A2 (en) 2019-05-08
AU2017290709A1 (en) 2019-01-24
RU2749109C2 (ru) 2021-06-04
AU2017290709B2 (en) 2024-08-01
EP3478723A4 (en) 2020-07-29
IL276515B1 (en) 2025-07-01
EP3478723B1 (en) 2025-12-17
WO2018005682A2 (en) 2018-01-04
IL263611A (en) 2019-01-31
CN109641960A (zh) 2019-04-16
US20180002424A1 (en) 2018-01-04
WO2018005682A3 (en) 2018-02-08
IL321335A (en) 2025-08-01
RU2019102009A (ru) 2020-07-28
JP7520072B2 (ja) 2024-07-22
BR112018076684A2 (pt) 2019-04-02
AU2024227032A1 (en) 2024-10-24
KR20220004763A (ko) 2022-01-11
CA3027204A1 (en) 2018-01-04
JP2019532013A (ja) 2019-11-07
SG11201810927QA (en) 2019-01-30
US20200277380A1 (en) 2020-09-03
IL263611B (en) 2020-08-31
US11834505B2 (en) 2023-12-05
KR102422411B1 (ko) 2022-07-18
US20240150468A1 (en) 2024-05-09
JP7148414B2 (ja) 2022-10-05
JP2022120008A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
NZ767596A (en) Antibodies that bind cd39 and uses thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
EP4417263A3 (en) Cd3 binding antibodies
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
PH12020552229A1 (en) Il-11ra antibodies
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2018069871A3 (en) Anti-kras binding proteins
EP3733703A4 (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
MX2020008122A (es) Anticuerpos anti-pd-1.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2018001964A (es) Polipeptidos mrka, anticuerpos y usos de los mismos.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.